

Supplemental Figure S1. Human CD20 expression by generated hCD20^{pos} B16 cells was analyzed by flow cytometry. **A**) 2 x 10^5 Daudi cells or hCD20^{pos} B16 cells (**B**) were incubated with 10 µg of Rituximab for 1h at 4°C. After washing the cells, Rituximab binding was detected by adding 1 µg of human anti-IgG1 PE mAb (clone IS11-12E4.23.20, Miltenyi Biotec) for 30 min at 4°C. After washing, mean fluorescence intensity (MFI) was measured using a FACS Canto Flow Cytometer (BD) and analyzed with Flow Jo 7 software (Tree Star Inc., Ashland, Oregon, USA). Background controls included: unstained Daudi and hCD20pos B16 cells, and Daudi and hCD20^{pos} B16 cells incubated with anti-HER2 Trastuzumab mAb (isotype control) and further processed as described above. **C**) A comparable hCD20-expression was observed between Daudi and hCD20^{pos} B16 cells.